A hot flash on tamoxifen metabolism.
Goetz
Matthew P
MP
Loprinzi
Charles L
CL
D018687:Antidepressive Agents, Second-Generation / Q000493:pharmacokinetics*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000493:pharmacokinetics*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D003511:Cyclohexanols / Q000493:pharmacokinetics; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism*; D020847:Estrogen Receptor Modulators / Q000009:adverse effects / Q000493:pharmacokinetics*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D005473:Fluoxetine / Q000493:pharmacokinetics; D019584:Hot Flashes / Q000139:chemically induced; D006801:Humans; D006900:Hydroxylation; D017374:Paroxetine / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000493:pharmacokinetics*; D013629:Tamoxifen / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000493:pharmacokinetics*; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D018931:Antineoplastic Agents, Hormonal; D003511:Cyclohexanols; D020847:Estrogen Receptor Modulators; D020845:Selective Estrogen Receptor Modulators; D005473:Fluoxetine; D013629:Tamoxifen; C016601:afimoxifene; D017374:Paroxetine; D000069470:Venlafaxine Hydrochloride; D019389:Cytochrome P-450 CYP2D6; C028787:N-desmethyltamoxifen